Navigation Links
Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
Date:4/20/2011

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection. Through the collaboration with the University of Minnesota and James Cloyd, PharmD; Neurelis has partnered with the leading experts in clinical research of the nasal delivery of benzodiazepines.  Results from this important study are expected in June.

"We are pleased to work with Dr. Cloyd and the University of Minnesota to complete dosing in the first human trial of our unique nasally administered formulations of diazepam," stated David Hale, Chairman.  "Neurelis has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures.  These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits."

Intranasal diazepam is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute breakthrough seizure activity. There are over 2.7 million people with epilepsy in the United States.  It is estimated that between 30% to 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

Presently, there is only one product approved for the treatment of acute repetitive seizures outside of the acute care setting, which is a rectally administered formulation of diazepam called Diastat®.  Because of its rect
'/>"/>

SOURCE Neurelis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... , SAN DIEGO, Nov. 24 ... present at the 21st Annual Piper Jaffray Health Care Conference at ... 2009 at 1:00 p.m. Eastern Time. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ... accessible on the Investors page of the Company,s website at ...
... , CINCINNATI, Nov. 23 HealthWarehouse.com, ... today announced its financial results for the third quarter ended ... driven by heavy growth in prescription sales and pharmacy transfers. ... loss for the quarter was $619,114 compared to a net ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Retardation -, PHILADELPHIA, Oct. 9 When ... ring before birth, they may,disrupt normal development and ... Children,s Hospital of Philadelphia will be investigating,one such ... Ring Chromosome,20 Foundation., Ring chromosome 20 syndrome, ...
... 9 House Republican Whip Roy,Blunt (Mo.) issued ... Clyburn (D-S.C.) yesterday suggested on CNN that Democrats ... the president,s veto of the,SCHIP bill:, "Yesterday, ... be,hard-pressed to override the president,s veto of a ...
... Quebec City, October 9, 2007People who experience chronic job ... of suffering from a second one, reports a research ... October 10 issue of the Journal of the American ... clearly demonstrate the risks associated with job strain for ...
... Oct. 9 Recent studies by Best,Practices, LLC ... 34 R&D,FTE,s per Quality FTE in Pharmaceutical companies. ... employees to effectively use a,Risk-Based Approach. Does your ... structure for Quality Assurance in R&D? What tools,are ...
... WASHINGTON, Oct. 9 The following was released,today by ... EDT, MR. TENPAS: Good morning. I am ... and Natural Resources Division here at the,Department of ... EPA,s,assistant administrator for Enforcement and Compliance Assurance., ...
... to boost abstinence, study finds , , TUESDAY, Oct. 9 ... seizures could be added to the short list of ... new study suggests. , The drug topiramate proved measurably ... from heavy drinking, the study authors said. , "Not ...
Cached Medicine News:Health News:Grant Supports Study of Abnormal Ring-Shaped Chromosomes 2Health News:Chronic job strain doubles the risk of a second heart attack 2Health News:Best Practice Database: Complimentary Excerpt of Pharma Quality Assurance Toolkit Available from Best Practices, LLC 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: